All Mergers and acquisitions articles – Page 2
-
BusinessPfizer’s Upjohn to merge with Mylan
Deal combines Pfizer’s off-patent drug portfolio with Mylan’s generics
-
BusinessUS judges slash damages in glyphosate cancer lawsuits
While upholding rulings linking the herbicide to cancer, judges have cut Bayer-Monsanto’s fines from billions to tens of millions of dollars
-
BusinessAbbVie to acquire Allergan in multibillion-dollar merger
Takeover deal will create world’s fifth-largest pharma company
-
OpinionIs Bayer regretting its Monsanto takeover?
Large damages in Roundup litigation have got investors questioning the move
-
BusinessJury awards $2bn damages in US glyphosate trial
Bayer vows to appeal third defeat over Monsanto’s Roundup weedkiller, while experts suggest damages will likely be reduced
-
BusinessPower-hungry Tesla picks up supercapacitor maker
Maxwell Technologies deal highlights potential for supercapacitors in electric vehicles and beyond
-
-
BusinessBattling the US opioid epidemic
Adapt pharma’s naloxone nasal spray makes treating overdoses easier
-
BusinessBristol-Myers Squibb to buy Celgene for $74 billion
Deal boosts BMS’s cancer and immunology pipeline with 5 drugs in late stage clinical trials
-
BusinessGSK and Pfizer joint venture creates new consumer healthcare giant
Enlarged GSK consumer health will have largest market share of any firm and be a leader in key countries
-
BusinessChemicals industry roundup 2018
Industry growth remains strong despite tariff disputes, political uncertainty and supply chain challenges
-
BusinessPharmaceuticals roundup 2018
Merger deals, product approvals and infrastructure changes have been overshadowed by political uncertainty, in Europe and around the world
-
BusinessBayer to cut 12000 jobs
As it integrates Monsanto businesses, Bayer will eliminate around 10% of its global workforce
-
BusinessSensing the sweet spot
Ziylo’s selective glucose-binding molecule could open doors to smart insulin for diabetes
-
BusinessNovartis to cut over 2000 jobs
Move exemplifies a wave of manufacturing cuts as pharma moves to more high-value, specialised medicines
-
BusinessTakeda set to swallow Shire
Shire’s US revenue and rare diseases portfolio grab Japanese firm’s attention
-
BusinessNovartis’ $8.7bn AveXis deal shows gene therapy appeal
Acquisition indicates the value of potentially permanent cures for inherited diseases
-
BusinessAkzoNobel sells off specialty chemicals arm in €10bn deal
Private equity firm Carlyle sees off several other bidders
-
SponsoredPharma and academia: a recipe for success
More big pharmaceutical companies are collaborating with universities
-
BusinessIndian court seizes former Ranbaxy owners’ assets
Daiichi Sankyo inches closer to recovering money from Singh brothers